A Randomized, Open-label, Multicenter, Controlled, Parallel Arm, Phase III Study Assessing the Efficacy and Safety of AOP2014 vs. Hydroxyurea in Patients With Polycythemia Vera

Trial Profile

A Randomized, Open-label, Multicenter, Controlled, Parallel Arm, Phase III Study Assessing the Efficacy and Safety of AOP2014 vs. Hydroxyurea in Patients With Polycythemia Vera

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2018

At a glance

  • Drugs Ropeginterferon alfa-2b (Primary) ; Hydroxycarbamide
  • Indications Polycythaemia vera
  • Focus Registrational; Therapeutic Use
  • Acronyms PROUD; PROUD-PV
  • Sponsors AOP Orphan Pharmaceuticals AG
  • Most Recent Events

    • 17 Jun 2018 Two-year analysis results from the Proud/Continuation phase III trials in two age cohorts (less than 60 years and greater than or equal to 60 years), presented at the 23rd Congress of the European Haematology Association.
    • 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association
    • 25 Jun 2017 According to an AOP Orphan Pharmaceuticals AG media release, latest results from the study were presented at the 22nd Congress of the European Hematology Association (EHA) 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top